PRELIMINARY CLINICAL ASSESSMENT AND NON- TOXICITY EVALUATION OF AN AYURVEDIC FORMULATION BGR-34 IN NIDDM

B. P. Gupta, I. Sharma, N. Kohli, S. Sharma, A. Rathi, A. K. Sharma*

ABSTRACT

In view of the overall health impact of NIDDM, inventers understand the necessity of improving glycaemic control in adults with type 2 diabetes. BGR-34 provides an effective treatment option for adults with type 2 diabetes who have been inadequately controlled on lifestyle with or without other oral hypoglycaemic agents (OHGAs) such as metformin, sulfonylurea, or a glitazones. BGR-34 is an appropriate option to consider for addition to a managed care drug formulary. Treatment with BGR-34 produced clinically relevant and statistically significant reductions in all three key measures of glucose control studied —FPG, PPBG and HbA1c— when compared with placebo. This study has been registered in the clinical trial registry-India.

Keywords: BGR-34, Berberis aristata, NIDDM, Indian System Medicine, type 2 diabetes.